ClinicalTrials.gg
CompletedNCT06567470CitydreamUpdated Oct 19, 2026

A Study With CIT-013 in RA Patients

A Phase 2 interventional study of CIT-013 low dose and CIT-013 high dose in Rheumatoid Arthritis, sponsored by Citryll BV. Completed at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Citryll BV · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Arthritis, Rheumatoid with a site in Poland — 13 open to participants now, 22 under way, 3 of them phase 3. Arthritis, Rheumatoid · Poland.

Enrollment
232nd of 284
96 · median 292
Started
2025
with 11 others
Phase 2
141 of 290
6 open now
Registered
272nd of 290
by date

Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, this one is the 232nd largest by enrollment of the 284 interventional ones that give a count, is one of 12 that started in 2025, is one of 141 in phase 2, and was the 272nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

13 of the 290 studies in Arthritis, Rheumatoid with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Arthritis, Rheumatoid with a site in Poland, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if CIT-013 works to treat rheumatoid arthritis in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are:

Does CIT-013 lower the disease activity of RA patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of RA.

Participants will:

Take receive CIT-013 or placebo every other week for 6 weeks and 50 mg CIT-013 for 6 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients with RA according to the 2010 classification criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) ≥ 3 months prior to screening
  • Aged 18-85
  • DAS28-CRP ≥ 3.2, with ≥ 3 Swollen Joints, and ≥ 3 Tender Joints, and CRP ≥ at screening and confirmed prior to randomization
  • Stable on a conventional synthetic disease modifying antirheumatic drug for ≥ 4 weeks (csDMARD). This drug must have been used for ≥ 3 months.

Exclusion criteria

Exclusion Criteria:

  • High clinical activity or disease severity requiring the immediate start of a biological DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD).
  • for CIT-013
  • Current inflammatory joint disease other than RA (Sjogren with active disease is included).
  • The for bDMARD or JAKi prior to the first dose of product should be at least:

    1. ≥ 1 week for etanercept;
    2. ≥ 4 weeks for adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, and sarilumab;
    3. ≥ 6 months year for rituximab;
    4. ≥ 2 weeks for tsDMARD (either investigational or commercially available treatment).
  • Treated with ≥ 3 bDMARD or tsDMARD
  • Injectable or treatment with > 10 mg/day dose of oral prednisolone or equivalent within 4 weeks prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    CIT-013 low dose

    3 SC injections with low dose CIT-013 and 3 SC injections with medium dose CIT-013

    Drug: CIT-013 low dose

  • Experimental
    CIT-013 high dose

    3 SC injections with CIT-013 high dose and 3 SC injections with CIT-013 medium dose

    Drug: CIT-013 high dose

  • Placebo comparator
    Placebo

    3 SC injections with placebo and 3 SC injections with CIT-013 medium dose

    Drug: Placebo

  • Experimental
    CIT-013 medium dose

    6 SC injections with CIT-013 medium dose

    Drug: CIT-013 medium dose

Interventions

06

What researchers measure

Primary outcomes

  1. The change in DAS28-CRP at week 6 compared to baseline

    Efficacy of CIT-013

    Time frame: week 6

Secondary outcomes

  1. Incidence of TEAEs as assessed by CTCAE

    Safety and tolerability of CIT-013

    Time frame: 12 weeks

  2. Maximum Plasma Concentration of CIT-013 before doses

    CIT-013 levels

    Time frame: 4, 6, 10 and 12 weeks

07

Study locations

20 sites
  • Site BE-01
    Leuven, Belgium
  • DE-04
    Bamberg, Germany
  • DE-05
    Berlin, Germany
  • DE-01
    München, Germany
  • DE-02
    München, Germany
  • NL-05
    Leeuwarden, Netherlands
  • NL-03
    Nijmegen, Netherlands
  • NL-01
    Rotterdam, Netherlands
  • PL-01
    Bialystok, Poland
  • PL-07
    Krakow, Poland
  • PL-03
    Lublin, Poland
  • PL-02
    Poznan, Poland
  • PL-05
    Torun, Poland
  • PL-04
    Warsaw, Poland
  • ES-02
    A Coruña, Spain
  • ES-04
    Barcelona, Spain
  • ES-05
    Barcelona, Spain
  • ES-06
    Madrid, Spain
  • ES-01
    Santander, Spain
  • ES-03
    Santiago de Compostela, Spain
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2026, 11 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 11 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Apr 2027 → Jul 2026 and completion Jul 2027 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 22, 2024
StartActual
Jul 29, 2025
Primary completionActual
Jul 2, 2026was Apr 2027
CompletionActual
Aug 11, 2026was Jul 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Sites
4 sites removed
Show 4 removed
  • BE-02 · Antwerp, Belgium
  • DE-03 · Ratingen, Germany
  • NL-02 · Amsterdam, Netherlands
  • NL-04 · Leiden, Netherlands
Oct 19, 2026
Primary completion
Apr 2027→Jul 2, 2026 (actual)
Oct 19, 2026
Study completion
Jul 2027→Aug 11, 2026 (actual)
Oct 19, 2026
Enrollment
88 (estimated)→96 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    4 sites removed
    Show 4 removed
    • BE-02 · Antwerp, Belgium
    • DE-03 · Ratingen, Germany
    • NL-02 · Amsterdam, Netherlands
    • NL-04 · Leiden, Netherlands
    Primary completion Apr 2027→Jul 2, 2026 (now actual)
    Study completion Jul 2027→Aug 11, 2026 (now actual)
    Enrollment 88 (estimated)→96 (actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06567470
Lead sponsor
Citryll BV
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Jul 29, 2025
Primary completion
Jul 2, 2026
Completion
Aug 11, 2026
Last update
Oct 19, 2026

Study contacts

Maarten Kraan
study director · Citryll BV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CIT-013

Start the discussion